In a trial by Iepsen et al., 37 women with an average age of 46 (Standard Deviation: 2 years, range 18-65 years) and BMI of 34 (SD: 0.5 kg/m 2 ) achieved a 12% weight loss after 8 weeks of low-calorie diet modifications
In contrast to other AOMs, which either suppress appetite or inhibit fat absorption [23], GLP-1RAs reduce body weight in a number of ways, decreasing appetite and hunger, and increasing satiety, resulting in reduced energy intake [24,25,26]
Osteoporosis in anorexia nervosa
Click [...] To view or add a comment, sign in $NVO has started a Phase 1 trial for its new obesity drug candidate LX9851, developed with Lexicon Pharmaceuticals The drug is oral and works differently from current GLP-1 treatments, targeting fat metabolism and satiety signals The study will assess safety in overweight and obese patients, with results expected in Q1 2027 Lexicon receives a $10M milestone payment and could earn up to $1B plus royalties if successful #stocks #Investing To view or add a comment, sign in 16,852 followers
Tara *Based on internal survey 416 GLP-1 users in 2025 **Based on survey responses of 166 participants in a 6-month clinical trial who had overweight or obesity, and were taking semaglutide/tirzepatide for weight loss within the WW Clinic Program and participating in the GLP-1 companion nutrition program
A 2025 study in mice showed that prenatal glyphosate exposure at normal levels reshapes the gut microbiome
